At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
Tipifarnibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations
In Brief
A Phase 2 clinical trial evaluating Tipifarnib for Thyroid Cancer and 3 related conditions. Completed, enrolled 63 participants across 35 sites in 10 countries.
Detailed Summary
Phase II study to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with advanced tumors that carry HRAS mutations and for whom there is no standard curative therapy available.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor, Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor
CountriesBelgium, France, Germany, Greece, Italy, Netherlands, South Korea, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartMay 2015
Primary CompletionDec 2020
TodayJul 2026
First PostedMar 10, 2015
Enrollment StartMay 13, 2015
Primary CompletionDec 14, 2020
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 11.3 years ago
Interventions
Tipifarnibdrug
FTase inhibitor